BioCentury
ARTICLE | Clinical News

Ushercell: Phase I

November 22, 1999 8:00 AM UTC

Data from about 45 patients showed that Ushercell gave minimal evidence of vaginal irritation. The company plans to conduct long-term toxicology and both contraceptive and anti-STD Phase II studies. ...